Safety, Tolerability and Efficacy of AVP-786 for the Treatment of Disinhibition

Phase 2 Terminated NCT02534038

Condition	Disinhibition Syndrome
Phase	Phase 2
Sponsor	Otsuka Pharmaceutical Development & Commercialization, Inc.
Status	Terminated
Enrollment	1 participants
Interventions	AVP-786
Start date	Dec 1, 2015
Completion date	Oct 3, 2017
Results posted	Oct 26, 2020

Summary

Treatment of disinhibition syndrome in participants with Neurodegenerative Disorder.

Change From Baseline in the Disinhibition Domain of the Neuropsychiatric Inventory (NPI)

Baseline; Week 6, Week 8, and Week 14

Open in BENITIONS View on ClinicalTrials.gov

All trials

This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.

English 한국어 日本語中文 Русский